Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 4.5%

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price rose 4.5% during trading on Thursday . The stock traded as high as $12.26 and last traded at $12.25. Approximately 228,273 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 960,156 shares. The stock had previously closed at $11.72.

Wall Street Analysts Forecast Growth

Several analysts recently commented on STOK shares. TD Cowen raised shares of Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 26th. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. lifted their price target on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a "neutral" rating in a report on Tuesday, March 26th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Thursday, April 11th. Finally, Wedbush increased their price objective on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $19.63.

Stoke Therapeutics Price Performance

The firm has a market capitalization of $539.40 million, a price-to-earnings ratio of -5.01 and a beta of 0.77. The business's fifty day simple moving average is $8.47 and its 200 day simple moving average is $5.89.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 25th. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.02. The business had revenue of $2.80 million for the quarter, compared to analysts' expectations of $3.70 million. Equities research analysts expect that Stoke Therapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the completion of the transaction, the insider now owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares of the company's stock, valued at approximately $125,786,699.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the transaction, the insider now owns 6,981 shares of the company's stock, valued at $33,508.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,632,741 shares of company stock worth $41,983,115. Insiders own 12.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of Stoke Therapeutics by 24.3% in the second quarter. BlackRock Inc. now owns 2,293,670 shares of the company's stock valued at $24,382,000 after acquiring an additional 448,175 shares during the period. Vanguard Group Inc. boosted its holdings in Stoke Therapeutics by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,047,904 shares of the company's stock valued at $26,295,000 after purchasing an additional 52,871 shares during the period. Lynx1 Capital Management LP purchased a new position in shares of Stoke Therapeutics during the 3rd quarter valued at $6,738,000. Goldman Sachs Group Inc. grew its position in Stoke Therapeutics by 976.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,391,431 shares of the company's stock worth $7,319,000 after buying an additional 1,262,126 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in Stoke Therapeutics in the 1st quarter worth about $25,011,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.